Profile data is unavailable for this security.
About the company
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
- Revenue in USD (TTM)2.60m
- Net income in USD-224.53m
- Incorporated1983
- Employees186.00
- LocationCelldex Therapeutics Inc53 Frontage Road, Suite 220HAMPTON 08827United StatesUSA
- Phone+1 (908) 454-7120
- Fax+1 (908) 454-1911
- Websitehttps://celldex.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novavax Inc | 1.06bn | 341.75m | 1.41bn | 952.00 | 4.84 | -- | 3.75 | 1.33 | 1.80 | 1.80 | 6.29 | -0.9643 | 0.7362 | 7.87 | 16.49 | 1,118,331.00 | 23.63 | -39.12 | 53.33 | -248.97 | 91.82 | -- | 32.10 | -67.41 | 2.24 | 17.15 | 2.66 | -- | -30.65 | 105.39 | 65.60 | -- | 47.71 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.42bn | 130.00 | -- | 5.67 | -- | 94.48 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Alvotech SA | 573.35m | 69.50m | 1.45bn | 1.01k | 22.17 | -- | 13.76 | 2.52 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.45bn | 61.00 | -- | 16.48 | -- | 23.18 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.47bn | 136.00 | -- | -- | -- | 8.67 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.49bn | 60.00 | -- | 5.32 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.51bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Celldex Therapeutics Inc | 2.60m | -224.53m | 1.53bn | 186.00 | -- | 2.55 | -- | 587.82 | -3.38 | -3.38 | 0.0392 | 9.01 | 0.0035 | -- | 5.52 | 13,978.49 | -30.51 | -27.70 | -32.24 | -29.29 | -- | -- | -8,635.85 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
| Relay Therapeutics Inc | 8.36m | -297.59m | 1.55bn | 188.00 | -- | 2.54 | -- | 185.23 | -1.75 | -1.75 | 0.0491 | 3.52 | 0.0104 | -- | -- | 32,015.33 | -37.20 | -31.62 | -39.14 | -32.85 | -- | -- | -3,561.43 | -1,130.74 | -- | -- | 0.00 | -- | -60.83 | -- | 1.25 | -- | -24.08 | -- |
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.55bn | 123.00 | -- | 4.67 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.55bn | 74.00 | -- | 9.26 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.56bn | 28.00 | -- | 3.22 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.56bn | 31.00 | -- | 19.42 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.59bn | 65.00 | -- | 3.33 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.60bn | 317.00 | -- | 2.95 | -- | 19.10 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Agios Pharmaceuticals Inc | 54.03m | -412.78m | 1.64bn | 539.00 | -- | 1.37 | -- | 30.32 | -7.12 | -7.12 | 0.932 | 20.41 | 0.0365 | 0.2096 | 7.36 | 100,237.50 | -27.89 | -10.70 | -29.52 | -11.34 | 88.26 | -- | -764.01 | -516.35 | 11.06 | -- | 0.00 | -- | 48.03 | -- | -161.27 | -- | -21.96 | -- |
Data as of Feb 13 2026. Currency figures normalised to Celldex Therapeutics Inc's reporting currency: US Dollar USD
63.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2025 | 8.08m | 12.16% |
| Kynam Capital Management LPas of 30 Sep 2025 | 6.10m | 9.18% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.55m | 6.85% |
| Point72 Asset Management LPas of 30 Sep 2025 | 3.89m | 5.86% |
| Bellevue Asset Management AGas of 30 Sep 2025 | 3.56m | 5.35% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 3.55m | 5.34% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.52m | 5.29% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.40m | 5.11% |
| Commodore Capital LPas of 30 Sep 2025 | 3.03m | 4.56% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 2.31m | 3.47% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
